Dutasteride + Tamsulosin Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 0.5 mg + 0.4 mg
Reference Brands: Jalyn (USA), Dutamul (India), Duodart (EU)
Category:
Urology
Dutasteride + Tamsulosin is available in Capsules
and strengths such as 0.5 mg + 0.4 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dutasteride + Tamsulosin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dutasteride + Tamsulosin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Fixed-dose dutasteride/tamsulosin is a combination therapy used for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE). This formulation contains two active ingredients: tamsulosin and dutasteride. Tamsulosin is an α-adrenoceptor blocker that is relatively selective for the α1A-adrenoceptor subtype in the smooth muscles of the prostate, bladder neck, and prostatic urethra. By inhibiting these receptors, tamsulosin promotes relaxation of smooth muscle, improving urinary flow and relieving symptoms such as weak stream, hesitancy, and frequent urination.
Dutasteride is a 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT) in the prostate, liver, and skin. By reducing DHT levels, dutasteride causes shrinkage of prostatic epithelium and decreases overall prostate size, addressing the structural component of BPE.
Although no clinical studies have specifically evaluated the fixed-dose combination tablet, multiple trials on combination therapy of 5α-reductase inhibitors and α-adrenoceptor blockers, including the CombAT study, have shown significant improvements in LUTS symptom scores compared to monotherapy with either agent. This evidence supports the rationale for combining dutasteride and tamsulosin into a single tablet, offering both symptomatic relief and long-term reduction in prostate size in men with BPE.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing